Multiple Ascending Dose Study of AMG 598 in Subjects With Obesity
Status:
Completed
Trial end date:
2019-12-16
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, multiple ascending dose study in
subjects with obesity. AMG 598 will be evaluated in approximately 108 subjects to assess
safety, tolerability, pharmacokinetics and pharmacodynamic effects.